Table 2.
Efficacy and side effects of different doses of GnRH antagonist at 52 weeks
| Elagolix | Linzagolix | Relugolix | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Assessments | 150 mg Elaris-III |
200 mg Elaris-III |
150 mg Elaris-IV |
200 mg Elaris-IV |
75 mg | 100 mg | 200 mg | 40 mg CT Spirit-1 |
40 mg CT Spirit-2 |
| Pelvic Pain (OPP) | - | - | - | - | 69.2 | 53.8 | 82.4 | - | - |
| Dysmenorrhea (% responders) |
52.1 | 78.1 | 50.8 | 75.9 | 69.2 | 69.2 | 64.7 | - | - |
| NMPP (% responders) |
67.8 | 69.1 | 66.4 | 67.2 | 69.2 | 53.8 | 76.5 | - | - |
| BMD loss lumbar spine (%) | −0.63 | −3.60 | −1.10 | −3.91 | −1.14 | −1.40 | −2.19 | - | - |
| Hot flushes % | 44 | 72 | 36 | 77 | 22 | 27 | 60 | - | - |
Elagolix 150 mg once daily, elagolix 200 mg twice daily, linzagolix 75 mg, 100 mg and 200 mg once daily). Patients randomized to linzagolix 200 mg were switched to linzagolix 100 mg at week 24.